Changsha, China – 18 Sep 2026 – The Hunan Provincial Healthcare Security Bureau issued Notice Xiang Yi Bao Zhao Cai Han [2026] No. 114, implementing the results of its 2026 province‑wide price governance campaign for traditional Chinese medicine (TCM) decoction pieces and formula granules. The notice applies price‑risk markings to flagged products, orders manufacturers to cut listed prices exceeding 10 times the anchor price by 17:00 on 24 September 2026, imposes listing suspensions of at least three months on non‑compliant products, and confirms that new listing applications resume on 1 October 2026.
Policy Snapshot
| Item | Detail |
|---|---|
| Agency | Hunan Provincial Healthcare Security Bureau (China) |
| Document | Notice on Implementing the 2026 Price Governance Results for TCM Decoction Pieces and Formula Granules (Xiang Yi Bao Zhao Cai Han [2026] No. 114) |
| Legal Basis | Notice on Launching Price Governance of Listed Prices for TCM Decoction Pieces and Formula Granules (Xiang Yi Bao Zhao Cai Han [2026] No. 103) |
| Scope | TCM decoction pieces and formula granules listed on Hunan’s provincial procurement platform |
| Key Deadline | 17:00, 24 Sep 2026 – cut listed prices to within 10x the anchor price |
| Sanctions | Listing suspension (from 3 months) for missed price cuts, unestablished distribution relationships, or non‑conforming invoice information |
| Appeal Window | 3 months from the price‑risk‑flagging date, via the appeal module of the procurement subsystem |
| Channel Reopening | Listing applications and filing‑to‑sunshine‑listing conversions accepted again from 1 Oct 2026 |
| Affected Products | Not disclosed in the notice body; itemized in five annexed lists |
Governance Measures in Detail
- Price‑Risk Flagging: Products whose manufacturers lowered listed prices within the designated window have been cross‑checked against provincial transaction data and marked with price‑risk flags in the bidding‑and‑procurement subsystem of the Hunan Healthcare Insurance Information Platform. Enterprises may review their flags directly; companies that later cut prices into compliance will have flags adjusted periodically under the stated rules.
- Anchor‑Price Correction (10x Rule): Listed prices more than 10x the anchor price (10x itself excluded) fall within the correction scope. Manufacturers must reprice by the 24 September deadline; products that miss it – absent a pending complaint or appeal – will be suspended from the platform, while products under active appeal will be disposed of per the appeal handling opinions.
- Compliance‑Based Suspensions: Separate suspensions (effective from the notice’s publication date, running at least three months) apply to products whose enterprises failed to establish required distribution relationships or whose invoice information remained non‑conforming after self‑inspection. Enterprises that subsequently remediate may apply for listing restoration.
- Due‑Process Safeguards: A three‑month appeal window via the subsystem’s appeal module preserves a formal challenge path for companies disputing their risk flags.
- Application Resumption: From 1 October 2026, Hunan resumes accepting new listing applications for TCM decoction pieces and formula granules, as well as conversions from filing to sunshine listing – signaling a return to normal channel operations after the governance round.
Market Impact & Outlook
- Compliance Crunch: Manufacturers of flagged SKUs face a roughly six‑day repricing window between the notice date and the 24 September deadline – a tight turnaround that will test internal pricing governance at TCM producers selling into Hunan.
- TCM Price Discipline Trend: The anchor‑price mechanism extends the centralized‑procurement playbook from chemical drugs into the historically fragmented TCM decoction‑pieces and formula‑granules market, where wide price dispersion across provinces has drawn sustained regulatory scrutiny.
- Supply Continuity Risk: Suspensions of three months or longer could create temporary gaps in affected SKUs at Hunan public medical institutions; hospitals and distributors are advised to review the five annexed lists covering price‑correction products, missing distribution relationships, and invoice non‑conformities.
- Structural Signal: Pairing enforcement suspensions with a firm 1 October reopening suggests Hunan views this round as a market‑clearing exercise rather than a prolonged freeze, with ongoing periodic flag adjustments keeping price discipline continuous.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory deadlines, appeal outcomes, suspension durations, and the resumption of listing applications for TCM decoction pieces and formula granules in Hunan Province. Actual results may differ due to risks including appeal handling decisions, enterprise remediation progress, and subsequent policy adjustments by the Hunan Provincial Healthcare Security Bureau.-China Health Reform Pulse
Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202609/t20260918_34067089.html